The invention relates to the use of magnesium stearate in powder formulation for inhalation comprising carrier particles to inhibit or reduce chemical degradation of an active ingredient bearing a group susceptible to hydrolysis. A pharmaceutical formulation in form of dry powder for inhalation comprising (a) a carrier, (b) magnesium stearate, and a) an active ingredient substance susceptible to hydrolysis is also provided.